Earlier this week, Sophiris Bio (SPHS) released data from its Phase 2b trial for Prostate Cancer medication called “Topsaylysin,” and it didn’t exactly …
Sophiris (NASDAQ:SPHS) shares are shooting up 27% faster than Jack’s magic bean sparking right into a giant beanstalk. The reason?
Maxim’s Jason Kolbert is betting on SPHS to “unlock” share value with prostate cancer asset topsalysin.
Sophiris Bio Inc (NASDAQ:SPHS) provided an update on clinical trial enrollment of its Phase 2b study of topsalysin as a treatment for men …
Analyst Joseph Pantginis of H.C.
Sophiris Bio Inc (NASDAQ:SPHS) reported financial results for the three and six months ended June 30, 2017 and key corporate highlights. Key Corporate Highlights: Phase …
Drug maker Sophiris Bio Inc (NASDAQ:SPHS) released its earnings report for the first quarter of 2017 and is one step closer to beginning Phase …
Sophiris Bio Inc (NASDAQ:SPHS) reported first quarter financial results and key corporate highlights. Key Corporate Highlights: Update on Phase 2b Localized Prostate …
Following Sophiris Bio Inc’s (NASDAQ:SPHS) fourth-quarter and 2016 financial results released yesterday coupled with last week’s update on its prostate cancer program, Rodman …
Maxim analyst Jason Kolbert was out with a research note on Sophiris Bio Inc (NASDAQ:SPHS), following the company’s fourth-quarter financial results and update on its …